The AR gene amplification present in the only patient who showed a prolonged clinical benefit was intriguing, prompting to hypothesize the potential value of AR gene amplification as a predictive biomarker of response to AR agonists in BC (Figure 3). This evidence concerns the gene AR and breast cancer.